Currently, there are 774.70M common shares owned by the public and among those 752.53M shares have been available to trade.
The company’s stock has a 5-day price change of -3.13% and 56.26% over the past three months. XPEV shares are trading 75.30% year to date (YTD), with the 12-month market performance up to 165.30% higher. It has a 12-month low price of $6.55 and touched a high of $27.16 over the same period. XPEV has an average intraday trading volume of 12.57 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.79%, 8.29%, and 66.20% respectively.
Institutional ownership of XPeng Inc ADR (NYSE: XPEV) shares accounts for 16.26% of the company’s 774.70M shares outstanding.
It has a market capitalization of $16.05B and a beta (3y monthly) value of 2.63. The earnings-per-share (ttm) stands at -$0.85. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.57% over the week and 4.85% over the month.
Analysts forecast that XPeng Inc ADR (XPEV) will achieve an EPS of -1.51 for the current quarter, -1.39 for the next quarter and 1.76 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -2.03 while analysts give the company a high EPS estimate of -2.03. Comparatively, EPS for the current quarter was -1.49 a year ago. Earnings per share for the fiscal year are expected to increase by 75.15%, and 207.87% over the next financial year.
Looking at the support for the XPEV, a number of firms have released research notes about the stock. Nomura stated their Buy rating for the stock in a research note on March 19, 2025, with the firm’s price target at $14-$30. Daiwa Securities coverage for the XPeng Inc ADR (XPEV) stock in a research note released on March 19, 2025 offered a Neutral rating with a price target of $24. Citigroup was of a view on March 10, 2025 that the stock is Buy, while UBS gave the stock Neutral rating on February 24, 2025, issuing a price target of $8.80- $18. Macquarie on their part issued Neutral rating on February 07, 2025.
